Literature DB >> 33674285

Portable RT-PCR System: a Rapid and Scalable Diagnostic Tool for COVID-19 Testing.

Hosam M Zowawi1,2,3, Thamer H Alenazi4,2, Waleed S AlOmaim5, Ahmad Wazzan4,2, Abdullah Alsufayan6, Rihab A Hasanain7, Omar S Aldibasi4,2, Sahar Althawadi5, Sarah A Altamimi5, Maysoon Mutabagani5, Maha Alamri8, Reem S Almaghrabi8, Hail M Al-Abdely8, Ziad A Memish9,10,11, Saleh A Alqahtani12,13.   

Abstract

Combating the ongoing coronavirus disease 2019 (COVID-19) pandemic demands accurate, rapid, and point-of-care testing with fast results to triage cases for isolation and treatment. The current testing relies on reverse transcriptase PCR (RT-PCR), which is routinely performed in well-equipped laboratories by trained professionals at specific locations. However, during busy periods, high numbers of samples queued for testing can delay the test results, impacting efforts to reduce the infection risk. Besides, the absence of well-established laboratories at remote sites and low-resourced environments can contribute to a silent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These reasons compel the need to accommodate point-of-care testing for COVID-19 that meets the ASSURED criteria (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable). This study assessed the agreement and accuracy of the portable Biomeme SARS-CoV-2 system against the gold standard tests. Nasopharyngeal and nasal swabs were used. Of the 192 samples tested using the Biomeme SARS-CoV-2 system, the results from 189 samples (98.4%) were in agreement with the reference standard-of-care RT-PCR testing for SARS-CoV-2. The portable system generated simultaneous results for nine samples in 80 min with high positive and negative percent agreements of 99.0% and 97.8%, respectively. We performed separate testing in a sealed glove box, offering complete biosafety containment. Thus, the Biomeme SARS-CoV-2 system can help decentralize COVID-19 testing and offer rapid test results for patients in remote and low-resourced settings.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Biomeme; COVID-19; RT-PCR; point-of-care; portable

Year:  2021        PMID: 33674285     DOI: 10.1128/JCM.03004-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  3 in total

Review 1.  Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.

Authors:  Bidhan C Dhar
Journal:  Anal Bioanal Chem       Date:  2022-02-25       Impact factor: 4.478

2.  Strategies for the preparation of non-amplified and amplified genomic dengue gene samples for electrochemical DNA biosensing applications.

Authors:  Jahwarhar Izuan Abdul Rashid; Nor Azah Yusof; Jaafar Abdullah; Rafidah Hanim Shomiad Shueb
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

3.  Comparison of the Performance of 24 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in the Diagnosis of Coronavirus Disease 2019 Patients.

Authors:  Shiji Wu; Hongyan Hou; Huijun Li; Ting Wang; Wei Wei; Minxia Zhang; Botao Yin; Min Huang; Ziyong Sun; Feng Wang
Journal:  Front Microbiol       Date:  2022-08-08       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.